Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability

Tuberculosis (TB) remains the leading infectious cause of death worldwide, yet the only vaccine currently available is the pediatric BCG, which has poor effectiveness in preventing TB in adolescents and adults. A TB vaccine for this older age group is projected to prevent 4.6-8.5 million deaths by 2050 and increase gross domestic product by US$1.6 trillion by 2080, making this a priority investment for global stakeholders. In response to the World Health Organization's End TB Strategy, several TB vaccine candidates are now in phase III clinical trials, many of which target adolescents and adults. However, research on attitudes towards a TB vaccine is limited and urgently needed among these key populations to inform vaccine demand creation, scale up needs, and implementation strategies, particularly given global trends of increased vaccine hesitancy following the introduction of novel COVID-19 vaccines. To address this gap, a literature search was conducted for published studies evaluating socio-behavioral predictors of acceptability of HPV, COVID, and childhood immunizations as proxy indicators since there is a lack of published data on TB vaccine acceptability. We focused our search within Kenya and South Africa between January 2015 and July 2025 to represent high TB burden countries. Findings were supplemented with emerging data from unpublished conference abstracts on TB vaccine attitudes. Significant predictors of vaccine acceptability included higher perceived risk of disease, older age, a sense of collective responsibility, accurate and sufficient knowledge of the vaccine, trust in government or health authorities, and confidence in vaccine safety, side effects, and efficacy. Corresponding strategies to improve TB vaccine acceptability included early and accurate public communication, engagement of community influencers and youth, and use of diverse communication platforms.

Authors

Institutions

Publication Details

Journal
Vaccine
Published
2026-03-13
DOI
https://doi.org/10.1016/j.vaccine.2026.128457
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability

Adrienne E. Shapiro, Alexa Giovanatti
Vaccine
Tuberculosis Research and Epidemiology
article

Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability

Adrienne E. Shapiro, Alexa Giovanatti
article en

Abstract

Tuberculosis (TB) remains the leading infectious cause of death worldwide, yet the only vaccine currently available is the pediatric BCG, which has poor effectiveness in preventing TB in adolescents and adults. A TB vaccine for this older age group is projected to prevent 4.6-8.5 million deaths by 2050 and increase gross domestic product by US$1.6 trillion by 2080, making this a priority investment for global stakeholders. In response to the World Health Organization's End TB Strategy, several TB vaccine candidates are now in phase III clinical trials, many of which target adolescents and adults. However, research on attitudes towards a TB vaccine is limited and urgently needed among these key populations to inform vaccine demand creation, scale up needs, and implementation strategies, particularly given global trends of increased vaccine hesitancy following the introduction of novel COVID-19 vaccines. To address this gap, a literature search was conducted for published studies evaluating socio-behavioral predictors of acceptability of HPV, COVID, and childhood immunizations as proxy indicators since there is a lack of published data on TB vaccine acceptability. We focused our search within Kenya and South Africa between January 2015 and July 2025 to represent high TB burden countries. Findings were supplemented with emerging data from unpublished conference abstracts on TB vaccine attitudes. Significant predictors of vaccine acceptability included higher perceived risk of disease, older age, a sense of collective responsibility, accurate and sufficient knowledge of the vaccine, trust in government or health authorities, and confidence in vaccine safety, side effects, and efficacy. Corresponding strategies to improve TB vaccine acceptability included early and accurate public communication, engagement of community influencers and youth, and use of diverse communication platforms.

VaccineVol. 79
University of Washington (US)
Openalex Percentile: Top 24%
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability — Adrienne E. Shapiro, Alexa Giovanatti · Vaccine (2026) | TGRS Research Map | TGRS